Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI China ETF — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while iShares MSCI China ETF trades at $52.53 (market cap $5.94B). The key difference: iShares MSCI China ETF is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares MSCI China ETF for 63 Days on average.
| CRSP | MCHI | |
|---|---|---|
Market Cap | $4.88B | $5.94B |
Volume | 2,861,747 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $74.92 | $65.59 |
52-Week Low | $44.34 | $50.48 |
Typical Hold Time | 77 Days | 63 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
MCHI trades at $52.46, up 1.59% today, but faces strong bearish technical signals with 13 sell signals on moving averages. The ETF's valuation remains historically cheap compared to US indices, with Seeking Alpha noting the discount despite significant tech exposure. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions ahead of key US-China meetings.
Outlook remains cautious given bearish technicals and China's macroeconomic headwinds, though the valuation discount presents potential opportunity. Key risks include US-China trade tensions and weak domestic consumption. Institutional activity shows mixed signals with recent purchases by Empowered Funds offset by sales from Acima Private Wealth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
